RA Capital Management

RA Capital Management is a Boston-based healthcare and life sciences investment firm that combines hedge fund public market investing with venture capital and private equity investments in biopharmaceutical companies, managing more than $10 billion in assets. The firm was founded by Peter Kolchinsky, a scientist-turned-investor, and applies rigorous scientific diligence across all therapeutic areas. RA Capital invests with initial checks from $10 million to $100 million and maintains long-term positions. Portfolio companies include Argenx, the Dutch biopharmaceutical company developing antibody-based treatments for autoimmune diseases; Black Diamond Therapeutics, the clinical-stage precision oncology company; Imago BioSciences, acquired by Bristol-Myers Squibb for $1.35 billion; and Relay Therapeutics, the computational drug discovery company. Beyond its original investments, the portfolio includes additional clinical-stage biopharmaceutical companies.